Literature DB >> 29103749

Chemotherapy regimens containing taxanes or fluorouracil in nasopharyngeal carcinoma: Which better?

Jing-Lin Mi1, Bin Zhang2, Yu-Fei Pan3, Yi-Xin Su4, Jin-Fang Fan1, Shu-Fang Liao1, Xiao-Li Qin1, Da-Cheng Yao1, Hua-Ying Tang1, Wei Jiang5.   

Abstract

OBJECTIVES: The efficacy of various chemotherapy regimens in nasopharyngeal carcinoma (NPC) remains under debate. We compared the efficacy and toxicity of a taxane-based regimen and regimen including fluorouracil in NPC.
MATERIALS AND METHODS: Eight-hundred and six patients with stage II-IVB NPC from four institutions in China were pair-matched (1:1 ratio) to the cisplatin plus fluorouracil (PF) group or cisplatin plus taxanes (TP) group using eight clinical factors. Overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRRFS) and distant metastasis-free survival (DMFS) were assessed using the Kaplan-Meier method and Cox regression model. Toxicities were assessed in all patients.
RESULTS: Three-year DFS was significantly better in the TP group than PF group (82.5% vs. 72.7%, P=0.002), with no significant difference in OS, LRRFS or DMFS. TP led to significantly better DFS compared to PF in the subgroups advanced stage NPC, patients aged ≤45-years-old and female patients. In multivariate analysis, chemotherapy regimen was an independent prognostic factor for DFS [hazard ratio, 0.591, 95% CI 0.444-0.786, P=0.000]. Grade 3-4 leukopenia, neutropenia and anemia were significantly more common in the TP group; grade 3-4 mucositis, vomiting, vasculitis and diarrhea were more common in the PF group.
CONCLUSION: Taxane-based regimens have a higher efficacy in NPC than regimens including fluorouracil, especially in patients with advanced stage, patients aged≤45-years-old and female patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-Fluorouracil; Chemotherapy; Nasopharyngeal carcinoma; Radiotherapy; Taxane

Mesh:

Substances:

Year:  2017        PMID: 29103749     DOI: 10.1016/j.oraloncology.2017.09.003

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  3 in total

1.  A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC.

Authors:  Lifeng Xiao; Wenyi Kang; Jiayu Liao; Yuru Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-08-19       Impact factor: 3.236

2.  Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma?

Authors:  Yan He; Tao Guo; Jingjing Wang; Yu Sun; Hui Guan; Shaoyong Wu; Xingchen Peng
Journal:  Ann Transl Med       Date:  2019-03

3.  Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years).

Authors:  Jing-Lin Mi; Yi-Liang Meng; Hong-Liang Wu; Yi-Lin Cao; Bin Zhang; Yu-Fei Pan; Yuan-Yuan Zhou; Jin-Fang Fan; Shu-Fang Liao; Xiao-Li Qin; Da-Cheng Yao; Wei Jiang
Journal:  Strahlenther Onkol       Date:  2019-11-20       Impact factor: 3.621

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.